Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Case Report

Musculoskeletal Sequelae following COVID-19 mRNA Vaccination: A Case Report

Akhil Sharma a,*, Selene G. Parekh b

a Department of Orthopaedic Surgery, St. Luke's University Health Network, Bethlehem, PA, USA
b Department of Orthopaedic Surgery, Duke University Medical Center, Durham, NC, USA

ABSTRACT

Background: COVID-19 is among the most deleterious pandemics the world has ever faced. With millions of people now having received the unprecedented COVID-19 vaccines and many millions yet to receive it, it becomes imperative to determine the side effect profile of these vaccines.

Case report: Herein, we present a case in which a patient developed inflammatory fasciitis of the shoulder girdle and sternoclavicular joint inflammation requiring hospital admission following COVID-19 vaccination. The patient is a South Asian male of Indian origin residing in the United States.

Conclusion: Our report aims to share the scenario in which a patient developed severe pain, muscle spasms, inflammatory fasciitis in the shoulder and inflammation in the SC joint in the post-vaccination setting following the second dose of the Pfizer-BioNTech COVID-19 vaccine. To our knowledge, this is the first such reported case, and therefore this contribution of the presentation and pathogenesis of this orthopaedic complication may provide further information regarding clinically adverse effects from this nascent immunological advancement.

1. Introduction

The coronavirus (SARS-CoV-2) disease has cemented its place among the most deleterious pandemics the world has ever faced. Almost 300 million people have already been infected around the world, resulting in over 5 million deaths. Efforts to curtail the spread of this coronavirus have led to unparalleled measures by pharmaceutical companies to develop novel vaccinations.

Traditional vaccines with a history of longstanding public accessibility have been associated with certain predictable side effect panels, the vast majority of which are harmless. These adverse reactions are the result of an immune-mediated reaction to the vaccine excipient, the active components of the vaccine, or are related to immunodeficiency in the host. Clinically, the most common manifestations of a vaccine-related side effect are pain, swelling, and erythema at the injection site. More moderate symptoms commonly seen include systemic reactions such as fever, irritability, rash, and drowsiness. Rarer musculoskeletal side effects include swelling of the upper and lower extremities and inflammatory conditions such as myositis.

The introduction of new COVID-19 vaccines being offered through emergency use authorization in the U.S. as well as globally has revolutionized the landscape of vaccine science. Prior to this, the fastest that a vaccine had been developed and approved had been four years when the mumps immunization was released in the 1960s. The arrival of these vaccines is also rendered unique through the mechanism of the vaccines themselves; the first two COVID-19 vaccines to be authorized by the FDA, by Pfizer-BioNTech and Moderna, both utilize messenger RNA (mRNA), which has never before been approved for general use in humans. Previous publicly accessible vaccines contained viral proteins or inactive forms of the virus. However, with the extremely high efficacy of these vaccines during their clinical trials, this technique seems to have been validated and may direct the future of vaccine research.

Early research on the adverse reactions of these COVID-19 vaccines has demonstrated delayed injection site reactions, fever, fatigue, headache, myalgia, nausea, and skin rash. These reactions were more frequently reported in females, younger individuals, and after the mRNA-1273 vaccine. A unique depiction of multisystem inflammatory syndrome (MIS) in both children and adults has also been outlined in a landmark study from Japan. As we see the gradual decline in vaccine hesitancy and allow for longer longitudinal studies following multiple doses, it is likely we will discover additional side effects.

With millions of people now having received these unprecedented COVID-19 vaccines and many millions yet to receive it, it becomes imperative to determine the side effect profile of these vaccines. Therefore, we introduce a report of a patient who developed inflammatory fasciitis of the shoulder girdle and inflammation of the sternoclavicular joint.

* Corresponding author.
E-mail address: akhilsharma93@gmail.com (A. Sharma).

https://doi.org/10.1016/j.jorep.2022.100044

Received 20 April 2022; Received in revised form 13 May 2022; Accepted 14 May 2022
Available online 26 May 2022

2773-157X/© 2022 The Author(s). Published by Elsevier B.V. on behalf of Prof. PK Surendran Memorial Education Foundation. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
joint following administration of the second dose of Pfizer-BioNTech COVID-19 vaccine administration in January 2021. Included are data on the clinical presentation and treatment outcomes of the patient.

2. Case report

The patient is a 48 year old male from North Carolina of South Asian ethnicity, who works as a healthcare professional in a hospital system. His medical history prior to hospital admission in January was significant only for medication-controlled hypertension and hyperlipidemia. Surgical history consists of sublingual salivary cyst excision and nasal septum surgery. Home medications include rosuvastatin and olmesartan. He is a non-smoker, does not abuse alcohol or drugs, and his BMI was 23.7 upon admission.

3. Clinical findings

As a healthcare professional, he was offered the Pfizer-BioNTech COVID-19 vaccination by his hospital system in January 2021. Following his first dose, the patient did not have any symptoms. 21 days later, he received the second dose in his left shoulder, and only had mild soreness surrounding the injection site. Around noon the following day, he reported feeling a drop in his core internal body temperature. This subjective cold sensation lasted 8 h and subsided by the time the patient went to sleep that night.

However, the next day (two days after receiving the second dose), he began to have pain in his left neck, originating where it attached to the skull and radiating to his scalp, shoulder, and anterior pectorals. The pain intensified, and by the end of the day, he could barely lift his hand, and was having severe pain and spasms throughout the left upper quarter of his body. The patient tried heating and cooling packs, oral NSAIDs, lidocaine patches, but was not able to relieve his pain. Eventually, the pain localized to the left sternoclavicular (SC) joint. He was seen in clinic the following morning, where laboratory studies were drawn (Erythrocyte Sedimentation Rate, C-Reactive Protein, complete blood cell count with differential, and rheumatologic panel) and had an X-ray and ultrasound of his left SC joint taken. All laboratory studies were within reference range except for a CRP value of 4.34, marked elevated. His X-ray did not have any remarkable findings, but ultrasound revealed a fluid collection in the SC joint (Fig. 1).

4. Diagnostic assessment

Later that evening, his pain had exacerbated, and he developed spasms and a fever (Tmax 101.3 F), so he went to the Emergency Room. Due to his pain and spasming, he could not lay down for a physical exam until diazepam, ketorolac, morphine, and fentanyl were administered. Laboratory studies were drawn and an MRI of his left neck and shoulder were ordered, which showed inflammatory fasciitis throughout his left upper shoulder girdle, mild supraspinatus tendinitis, and enlarged cervical nodes (Fig. 2). He was admitted to the hospital, and pain was controlled with IV ketorolac and methocarbamol. Infectious Disease was consulted and performed a workup, ruling out an infectious source. Although wary of possibly blunting his COVID immune response, his managing physicians decided to administer a low-dose steroid for pain relief.

The patient's pain was controlled until his second day of admission, when his IV ketorolac was replaced with oral meloxicam. This change resulted in a pain score of 10 out of 10, and the patient required IV fentanyl for relief. His physicians then put him on a regimen of IV ketorolac, methocarbamol, gabapentin, and a hydromorphone patient-controlled analgesia pump. Although pain was controlled, the patient developed more severe spasms between his scapula and the medial border of his rhomboids. Eventually, his physicians gave him 60 mg of methylprednisolone and started him on a standing dose of 800 mg ibuprofen TID, 1000 mg acetaminophen TID, and gabapentin, methocarbamol, and oxycodone PRN. Four days after he was admitted to the hospital, the patient was discharged with a short course of prednisone, ibuprofen, and acetaminophen, which he took for one week before finally being free of pain and spasms.

At final follow up 12 months later, patient had no residual pain or lingering symptoms in the shoulder girdle or upper arm. No weakness or neurologic deficits were noted, and patient had made a full recovery.

Fig. 1. Musculoskeletal ultrasound of the sternoclavicular joint showing slight swelling and fluid collection.

Fig. 2. MRI of neck and shoulder showing inflammatory fasciitis throughout the patient's left upper shoulder girdle, mild supraspinatus tendinitis, and enlarged cervical nodes.
5. Discussion

Understanding the side effect profile of these novel mRNA vaccines designed to curtail COVID-19 will allow physicians to better identify, isolate and treat patients. Our report aims to share the scenario in which a patient developed severe pain, muscle spasms, inflammatory fasciitis in the shoulder and inflammation in the SC joint in the post-vaccination setting following the second dose of the Pfizer-BioNTech COVID-19 vaccine. To our knowledge, this is the first such reported case, and therefore this contribution of the presentation and pathogenesis of this orthopaedic complication may provide further information regarding clinically adverse effects from this nascent immunological advancement.

Our current recognition of the adverse reactions following vaccination comes from decades of research on accessible vaccines. Thus, we have come to expect mild to moderate pain, swelling, and erythema at the injection site following each dose of routine vaccinations such as influenza and hepatitis. However, very little is currently known about the effects of mRNA vaccines. In a recent study on 134 patients with cancer being actively treated by checkpoint inhibitors, Waissegrin et al. found that administration of the Pfizer BNT162b2 mRNA vaccine was most associated with pain, rash, and local swelling, whereas the most common systemic reactions were myalgia, fatigue, headache, fever, chills, and gastrointestinal complications. Kadali et al. investigated the side effects of the Moderna mRNA-1273 vaccine. After surveying 432 healthcare workers who had received the vaccine, authors disclosed many of the same side effects as the ones reported by Waissegrin et al. with the addition of muscle spasms, decreased sleep quality, brain fogging, flushing, heat/cold intolerance, and palpitations. Interestingly, the authors of both studies stated that none of the reported side effects from either vaccine required admission to the hospital or any other special intervention, unlike the patient in our report.

One possible explanation for the shoulder pain following vaccination is a rare condition called Parsonage-Turner Syndrome (PTS). PTS is a rare condition, but not phenomenon, which provides us with yet another clinical manifestation of the COVID-19 mRNA vaccines, rates of SIRVA are expected to rise sharply in the following years. Initially, our patient's managing physicians postulated that his sternoclavicular pain might be due to SC joint arthropathy, given localized pain and presence of fluid on ultrasound. However, this seems unlikely given absence of swelling and redness on physical exam, negative radiographic changes on X-ray, and lack of soft tissue swelling in the SC joint on MRI. Furthermore, arthropathy symptoms often last for a few months and are alleviated by NSAIDs, rarely requiring corticosteroids, neither of which are consistent with our patient's presentation. Finally, while SC joint arthropathy has been linked to traumatic and infectious etiologies, there is currently no post-vaccine association.

Herein, we present a case in which a patient developed inflammatory fasciitis of the shoulder girdle and sternoclavicular joint inflammation requiring hospital admission following COVID-19 vaccination. Initial concern was for infectious source given fever and mild systemic symptoms, although this was ruled out following workup by his physicians. Parsonage-Turner Syndrome may explain the pain and spasms, but our patient did not have any neurological sequelae such as weakness or sensory loss. The patient's clinical manifestations could possibly be attributed to SIRVA, as he experienced new onset shoulder and scapular pain shortly after the second dose and developed an inflammatory picture. Yet, the patient's intricate pain regimen including oscillating between IV opioids, NSAIDs, and steroids, as well as the presence of unexplained SC joint pain and inflammation makes the diagnosis more complex. The Pfizer representative at the patient's institution was equally perplexed, saying he had never seen any case like this one.

Of course, these vaccines have proven efficacy against COVID-19 and we wholeheartedly advocate for those who are able to get vaccinated against this virus that has uprooted so much. Nonetheless, the full array of the musculoskeletal side effect profile carried by these novel COVID-19 mRNA vaccines requires further investigation and monitoring as people continue to receive their doses and more cases begin to present themselves.

Financial support and sponsorship

No financial support or sponsorship was requested or received for this case report.

Informed consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given his consent for patient images and other clinical information to be reported in the journal. The patient understands that his names and initials will not be published and including IgG and IgM studies and vaccine specific antibodies. The results of the studies returned unremarkable for any rheumatological or auto-immune workup.

A new term, but not phenomenon, may provide us with yet another link explaining our patient's clinical picture. Shoulder injury related to vaccine administration (SIRVA) is a medicolegal term first introduced in 2010 to describe "shoulder pain with limited range of motion within 48 hours after vaccine receipt in individuals with no prior history of pain, inflammation, or dysfunction of the affected shoulder before vaccine administration." The pathophysiology is not understood, though consensus suggests an inflammatory response is generated when a vaccine is injected into tissues containing a preexisting antibody, resulting in bursitis. Though physical exam elicits severe pain and limited range of motion about the shoulder, neurological findings of weakness and sensory loss are less common. Imaging may be nonspecific in cases of SIRVA, and as such it remains a primarily clinical diagnosis. Treatment of SIRVA includes NSAIDs, corticosteroid injections, and physical therapy, with some cases requiring surgical intervention. SIRVA has been most discovered in cases of inactivated influenza vaccination, finding rates of up to 2.5%. Given both the novelty and the rampant global-scale distribution of the COVID-19 mRNA vaccines, rates of SIRVA are expected to rise sharply in the following years.
due efforts will be made to conceal his identity.

Authors contribution

AS was the primary author and gathered the information regarding the case and did the majority of the writing for the manuscript.

SGP was the principal investigator and wrote part of the manuscript, as well as providing editing and revision help.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

1. Ball P. The lightning-fast quest for COVID vaccines - and what it means for other diseases. Nature. 2021 Jan;589(7840):16–18. https://doi.org/10.1038/d41586-020-03626-1. PMID: 33400118.
2. Stone Jr CA, Rukasin CRF, Beachkofsky TM, Phillips EJ. Immune-mediated adverse reactions to vaccines. Br J Clin Pharmacol. 2019 Dec;85(12):2694–2706. https://doi.org/10.1111/bcp.14112. PMID: 31472022; PMCID: PMC6955412.
3. Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM. Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med. 2013 Jun 27;368(26):2487–2494. https://doi.org/10.1056/NEJMoa1303729. PMID: 23718156.
4. Waisengrin B, Agbarya A, Safadi E, Padova H, Wolf I. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. Lancet Oncol. 2021 May;22(5):581–583. https://doi.org/10.1016/s1470-2045(21)00135-8. PMID: 33812495; PMCID: PMC8016402.
5. Kimmel SR. Vaccine adverse events: separating myth from reality. Am Fam Physician. 2002 Dec 1;66(11):2113–2120. PMID: 12484693.
6. CDC. Pfizer-BioNTech COVID-19 Vaccine (also known as COMIRNATY): Overview and Safety. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.html (Accessed 22 April 2022).
7. Nune A, Iyergar KP, Goddard C, Ahmed AE. Multisystem inflammatory syndrome in an adult following the SARS-CoV-2 vaccine (MIS-V). BMJ Case Rep. 2021 Jul 29;14(7), e243888. https://doi.org/10.1136/bcr-2021-243888. PMID: 34326117; PMCID: PMC8323360.
8. Chan EWW, Leung MT, Lau LKW, et al. Comparing self-reported reactogenicity between adolescents and adults following the use of BNT162b2 (Pfizer-BioNTech) messenger RNA COVID-19 vaccine: a prospective cohort study. Int J Infect Dis. 2022 Mar;116:47–50. https://doi.org/10.1016/j.ijid.2021.12.354. PMID: 34965462; PMCID: PMC8710238.
9. Kitagawa H, Kaiya Y, Saiyama A, et al. Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan. J Infect Chemother. 2022 Apr;28(4):576–581. https://doi.org/10.1016/j.jiac.2021.12.034. PMID: 35058126; PMCID: PMC8747950.
10. Wiesel BB, Keeling LE. Shoulder injury related to vaccine administration. J Am Acad Orthop Surg. 2021 Sep;29(17):732–739. https://doi.org/10.5435/JAAOS-D-21-00021. PMID: 34185028.
11. Kadali RAK, Janagama R, Peruru S, et al. Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: a randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms. J Med Virol. 2021 Jul;93(7):4420–4429. https://doi.org/10.1002/jmv.26996. PMID: 34185028.
12. Feinberg JL, Radecki J. Parsonage-turner syndrome. HSS J. 2010 Sep;6(2):199–205. https://doi.org/10.1007/s11420-010-9176-x. PMID: 21886536; PMCID: PMC2926354.
13. Mahajan S, Zhang F, Mahajan A, Zimnowodzki S. Parsonage Turner syndrome after COVID-19 vaccination. Muscle Nerve. 2021 Jul;64(1):E3–E4. https://doi.org/10.1002/mus.27255. PMID: 33896680; PMCID: PMC8250573.
14. Nune A, Iyergar KP, Ish P, Varanula B, Musat CA, Sapkota HR. The Emergence of new-onset SLE following SARS-CoV-2 vaccination. QJM. 2021 Dec 20;114(10):739–740. https://doi.org/10.1093/qjmed/hcab229. PMID: 34450645.
15. Sternheim A, Chechik O, Freedman Y, Steinberg EL. Transient sternoclavicular joint arthropathy, a self-limited disease. J Shoulder Elbow Surg. 2014 Apr;23(4):548–552. https://doi.org/10.1016/j.jse.2013.08.013. PMID: 24332476.